Clinical Scorecard: Examining the Link Between a Modified Cardiometabolic Index and Cardiovascular Disease Risk in Adults with Early Cardiovascular-Kidney-Metabolic Syndrome: Findings from a Prospective Cohort Study

At a Glance

Key Highlights

• MCMI identified as an independent risk factor for CVD in CKM patients (HR: 1.07, p = 0.006)
• CKM syndrome stages 0-3 emphasize the importance of early screening and prevention
• Study utilized data from the nationally representative CHARLS cohort

Guideline-Based Recommendations

Diagnosis

• Utilize MCMI for assessing cardiovascular risk in CKM patients

Management

• Focus on lifestyle modifications and monitoring of metabolic parameters
• Consider pharmacological interventions for insulin resistance and dyslipidemia

Monitoring & Follow-up

• Regular assessment of fasting blood glucose, lipid profiles, and blood pressure

Risks

• Increased risk of CVD events in CKM patients with high MCMI scores

Patient & Prescribing Data

Middle-aged and elderly individuals with CKM syndrome

Emphasis on managing insulin resistance and metabolic abnormalities, including specific medications

Clinical Best Practices

• Implement routine screening for CKM syndrome in at-risk populations
• Encourage patient education on lifestyle changes to mitigate CVD risk
• Incorporate evidence-based practices from recent studies

References

• China Health and Retirement Longitudinal Study (CHARLS)
• American Heart Association (AHA) Guidelines